about
The Quest for Targets Executing MYC-Dependent Cell Transformation2′-Azido RNA, a Versatile Tool for Chemical Biology: Synthesis, X-ray Structure, siRNA Applications, Click LabelingStemness in Hydra - a current perspective.Inhibitor of MYC identified in a Kröhnke pyridine libraryHydra myc2, a unique pre-bilaterian member of the myc gene family, is activated in cell proliferation and gametogenesis.JAC, a direct target of oncogenic transcription factor Jun, is involved in cell transformation and tumorigenesisMolecular targets of the oncogenic transcription factor jun.Anti-apoptotic actions of insulin-like growth factors: lessons from development and implications in neoplastic cell transformation.Inhibition of Myc-induced cell transformation by brain acid-soluble protein 1 (BASP1).Expanding the Scope of 2'-SCF3 Modified RNA.Efficient access to 3'-terminal azide-modified RNA for inverse click-labeling patterns.Transcriptional control of DNA replication licensing by Myc.TOJ3, a target of the v-Jun transcription factor, encodes a protein with transforming activity related to human microspherule protein 1 (MCRS1).Conditional cell transformation by doxycycline-controlled expression of the MC29 v-myc allele.Suppression in transformed avian fibroblasts of a gene (CO6) encoding a membrane protein related to mammalian potassium channel regulatory subunits.Analyzing Myc in cell transformation and evolution.Electron detachment dissociation for top-down mass spectrometry of acidic proteins.Calcium-dependent binding of Myc to calmodulin.TOJ3, a v-jun target with intrinsic oncogenic potential, is directly regulated by Jun via a novel AP-1 binding motif.The metastasis-associated extracellular matrix protein osteopontin forms transient structure in ligand interaction sites.Structure and transcriptional regulation of BKJ, a novel AP-1 target gene activated during jun- or fos-induced fibroblast transformation.WS5, a direct target of oncogenic transcription factor Myc, is related to human melanoma glycoprotein genes and has oncogenic potential.Development of oral self nano-emulsifying delivery system(s) of lanreotide with improved stability against presystemic thiol-disulfide exchange reactions.Uptake of phenothiazines by the harvested chylomicrons ex vivo model: Influence of self-nanoemulsifying formulation designHydra Mesoglea Proteome Identifies Thrombospondin as a Conserved Component Active in Head Organizer RestrictionA Unique Family of Neuronal Signaling Proteins Implicated in Oncogenesis and Tumor SuppressionIn vitro transformation by the SV40 'early region' of cells from a human benign salivary gland tumor with a 12q13----q15 rearrangementCooperative cell transformation by Myc/Mil(Raf) involves induction of AP-1 and activation of genes implicated in cell motility and metastasisBackbone assignment of osteopontin, a cytokine and cell attachment protein implicated in tumorigenesisDifferential regulation of myc homologs by Wnt/β-Catenin signaling in the early metazoan HydraThe brain acid-soluble protein 1 (BASP1) interferes with the oncogenic capacity of MYC and its binding to calmodulin
P50
Q26744579-6163AB0B-7867-46BC-94D4-4BCD8B215E6CQ27676860-77938397-1C70-4972-97AB-7A573D7C6073Q27691827-112D1C03-EF2D-44CA-8A24-88839EE45A5BQ28656132-D656F84C-BD6E-4A45-8344-A74776D8B5E3Q33612813-246CD5B6-CD8A-4A27-9FC3-C2AC4FF5F816Q33949883-0A0822A8-392E-494F-B3E2-2B61249DCC1EQ35060829-1ABA4E97-A7CD-4295-BCC1-26DCCD55FBB1Q36754662-D40A0960-7DE4-4AD0-934C-6D34F8724EA1Q37153674-F350039A-F26D-49DE-8282-0FA5C8557EB4Q38298322-A0D3DB88-3E0A-4F74-8433-9265A4EEBAE8Q39041484-ABD1A737-E1D9-4660-9CF7-A6523DF7D3B1Q39048077-874FD2C1-BF22-4F1F-B545-7C87E09E902FQ40762434-B05EB7F7-ABB6-4663-B2FE-D7A8D9951EF4Q40977990-E6A87747-C29A-4FE5-A242-D7CA48316C07Q41121239-B4B12476-E889-4ED7-B1A8-D098F7DDA73DQ41983730-406F7C20-4842-459E-AFA3-ACFE71C93911Q42228520-4E01F82F-4889-4A0C-A729-88CCAEBCA9FEQ42315515-F9DF3D13-23E9-48B9-B586-E90825222843Q43745119-88BFEF6F-221C-48B0-AD33-C9895D86564FQ44096727-441BA493-D208-433A-8E8C-47C2C1B745CEQ47996532-5F8362DE-7203-4238-B855-B2E1CCD3E879Q48424196-A45A751D-4EF4-41AC-809F-8C74E3C5FF19Q54744070-FD473031-5F38-43EB-B4BB-07926E1B3E47Q57734500-81380F0E-51F7-4922-BD71-74E30F3BB76FQ58799604-1F038A80-CA38-4381-A0A2-6ED527E125F7Q64105333-DBDC1691-8433-444A-9217-421CAE4465E7Q68455025-CE33E9A9-EFBF-4876-819B-DE70723868B2Q82616798-A314F074-08CE-4EF1-95D1-963B00827EB4Q84303201-5B2D83F6-98E5-4D5A-8CB5-3B5136C1AC48Q92354388-C8AED139-9B90-4184-9A51-DBB96AAA8CC5Q92685784-D9C73280-3DE7-4375-9D2F-2DF68C57642F
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0001-7447-5920
@en
name
Markus Hartl
@ast
Markus Hartl
@en
Markus Hartl
@es
Markus Hartl
@nl
type
label
Markus Hartl
@ast
Markus Hartl
@en
Markus Hartl
@es
Markus Hartl
@nl
prefLabel
Markus Hartl
@ast
Markus Hartl
@en
Markus Hartl
@es
Markus Hartl
@nl
P106
P31
P496
0000-0001-7447-5920